IL6 blockade: an effective approach in steroid-refractory immune checkpoint inhibitor-related neuropathies requiring ICI rechallenge—case report
Abstract
Peripheral neuropathies due to immune checkpoint inhibitors (ICIs) treatment remain a common immune-related adverse event (irAEs).1-3 ICI-related neuropathies (irPNs) improve often after steroid and/or intravenous immunoglobulin (IVIg) treatment. They may, however, display resistance to immunomodulatory treatment or long-term functional sequelae. Additionally, no clear data are available on the management of ICI rechallenging after a treatment-refractory irPN. Tocilizumab is an interleukin-6 receptor (IL-6R) inhibitor approved in a variety of autoimmune diseases and described in cases of steroid-refractory irAEs.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Peripheral Neuropathies and Disorders
Prostate Cancer Treatment and Research
Publication details
- Journal / source
- ESMO Open
- Publisher
- Elsevier BV
- Volume
- 11
- Issue
- 1
- Pages
- 106026–106026
- Publication date
- 1 January 2026
- Language
- EN